Extending our analysis to breast cancer patients adjuvantly treated with tamoxifen, four late-type genes (EIF4B, RPL5, RPL3, EPN3), identified using our sequential validation strategy, were validated to be significantly associated with MFS in a meta-analysis including eight tamoxifen-treated breast cancer cohorts, when restricting the analysis to patients who were metastasis-free during the first three years after surgery. Here, EPN3 is linked to breast carcinoma.